A Phase 3 interventional study of Brimonidine and placebo in Rosacea, sponsored by Actavis Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-14.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.
Among the 11 studies testing brimonidine in Rosacea, this one has the largest enrollment, is one of 2 that started in 2014, is one of 4 in phase 3, and was the 8th registered.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2014.
This study's enrollment of 462 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 205 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 5 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing brimonidine in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea will be enrolled to have 413 in the modified intent-to-treat (mITT) population and 371 in the per-protocol (PP) population. Patients should have fewer than 3 facial inflammatory lesions, and moderate to severe erythema according to both Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of child bearing potential must not be pregnant or lactating at Screening and Randomization (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of must agree to the use of a reliable method of (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. A sterile sexual partner is not considered an adequate form of birth control.
All females will be considered to be of childbearing potential unless they:
Female patients of childbearing potential are defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
Drug: Brimonidine
Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
Drug: Brimonidine
Topical gel base only (Watson Laboratories Inc., USA)
Drug: placebo
Primary: Percentage of Treatment Success on Day 7
Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).
Time frame: 7 days
Percentage of Patients With a Clinical Response of Treatment Success on Day 1
Time frame: 1 day
| Milestone | Test: Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle |
|---|---|---|---|
| Started | 199 | 199 | 64 |
| Safety population | 199 | 199 | 64 |
| Mitt population | 191 | 193 | 58 |
| Pp population | 173 | 173 | 54 |
| Completed | 198 | 198 | 64 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).
| percentage of participants | Test: Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo |
|---|---|---|---|
| Primary: Percentage of Treatment Success on Day 7 | 9.95 | 10.36 | 0 |
| percentage of participants | Test: Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo |
|---|---|---|---|
| Percentage of Patients With a Clinical Response of Treatment Success on Day 1 | 30.89 | 30.89 | 8.62 |
Collected over Baseline to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test:Brimonidine 0.33% Gel | 26/199 (13.1%) | 0/199 (0%) | 26/199 (13.1%) |
| Reference: Mirvaso 0.33% Gel | 22/199 (11.1%) | 0/199 (0%) | 22/199 (11.1%) |
| Placebo Gel Vehicle | 4/64 (6.3%) | 0/64 (0%) | 4/64 (6.3%) |
| Event | Test:Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle |
|---|---|---|---|
| Burning sensationNervous system disorders | 4/199 | 9/199 | 0/64 |
| Application site erythemaGeneral disorders | 5/199 | 7/199 | 0/64 |
| FlushingVascular disorders | 6/199 | 5/199 | 1/64 |
| HeadacheNervous system disorders | 4/199 | 6/199 | 0/64 |
| Application site painGeneral disorders | 5/199 | 2/199 | 0/64 |
| Application site pruritusGeneral disorders | 4/199 | 2/199 | 1/64 |
| Back PainMusculoskeletal and connective tissue disorders | 0/199 | 0/199 | 1/64 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/199 | 0/199 | 1/64 |
| Application site warmthGeneral disorders | 2/199 | 2/199 | 0/64 |
| Dry MouthGastrointestinal disorders | 1/199 | 0/199 | 0/64 |
| Age, Categorical(Participants) | Test:Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 163 | 167 | 54 | 384 |
| >=65 years | 36 | 32 | 10 | 78 |
| Sex: Female, Male(Participants) | Test:Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle | Total |
|---|---|---|---|---|
| Female | 151 | 156 | 53 | 360 |
| Male | 48 | 43 | 11 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Test:Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 60 | 65 | 19 | 144 |
| Not Hispanic or Latino | 139 | 134 | 45 | 318 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test:Brimonidine 0.33% Gel | Reference: Mirvaso 0.33% Gel | Placebo Gel Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 198 | 198 | 64 | 460 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine